Short‐Term Weight Loss Outcomes of 1.0 mg Semaglutide Therapy Initiated 6 Months After Sleeve Gastrectomy
Authors' conclusion
Semaglutide initiated 6 months post LSG significantly enhances short-term postoperative weight loss, even among patients who have already achieved substantial initial weight loss. These findings suggest its potential as an effective adjunct therapy for optimizing weight management in early postoperative care.
Study context
- Population
- Patients undergoing primary laparoscopic sleeve gastrectomy (LSG); controls matched on demographics, preoperative BMI, WHR, comorbidities and total weight loss at 6 monthsmatched 1:3
- Participants
- 34 vs 102
- Exposure
- Semaglutide 1.0 mg weekly from 6 months post LSG vs no semaglutide
- Treatmentn = 34
- Controln = 102reference
- Outcome
- Absolute and percentage weight loss
- Follow-up
- 6 to 12 months post LSG
Methodological detailsmatched 1:3
- Matched 1:3
Main finding
As reported in the abstract
Absolute weight loss
P < 0.0001
Observational data: associations, not effects.
Further findings
| Outcome | Treatment | Control | P value |
|---|---|---|---|
| Percentage weight loss (primary outcome) · 6 to 12 months post LSGGreater with Treatment | 12.61% ± 4.11% | 4.84% ± 5.18% | P < 0.0001 |
| TWL · 6 months post LSG | 23.16% ± 6.50% | 23.53% ± 4.87% | |
| TWL · 12 monthsHigher with Treatment | 35.77% ± 8.35% | 28.37% ± 7.41% | P < 0.0001 |
Original publication
Short‐Term Weight Loss Outcomes of 1.0 mg Semaglutide Therapy Initiated 6 Months After Sleeve Gastrectomy. Obesity (Silver Spring). Published 18 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →